Cargando…
CT of Postacute Lung Complications of COVID-19
The acute course of coronavirus disease 2019 (COVID-19) is variable and ranges from asymptomatic infection to fulminant respiratory failure. Patients recovering from COVID-19 can have persistent symptoms and computed tomography (CT) abnormalities of variable severity. At 3 months after acute infecti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radiological Society of North America
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369881/ https://www.ncbi.nlm.nih.gov/pubmed/34374591 http://dx.doi.org/10.1148/radiol.2021211396 |
_version_ | 1783739375748644864 |
---|---|
author | Solomon, Joshua J. Heyman, Brooke Ko, Jane P. Condos, Rany Lynch, David A. |
author_facet | Solomon, Joshua J. Heyman, Brooke Ko, Jane P. Condos, Rany Lynch, David A. |
author_sort | Solomon, Joshua J. |
collection | PubMed |
description | The acute course of coronavirus disease 2019 (COVID-19) is variable and ranges from asymptomatic infection to fulminant respiratory failure. Patients recovering from COVID-19 can have persistent symptoms and computed tomography (CT) abnormalities of variable severity. At 3 months after acute infection, a subset of patients will have CT abnormalities that include ground glass abnormalities (GGO) and subpleural bands with concomitant pulmonary function abnormalities. At 6 months after acute infection, some patients have persistent CT changes to include the resolution of GGOs seen in the early recovery phase and the persistence or development of changes suggestive of fibrosis such as reticulation with or without parenchymal distortion. Predictors of post-COVID lung disease include need for intensive care unit (ICU) admission, mechanical ventilation, higher inflammatory markers, longer hospital stay and a diagnosis of acute respiratory distress syndrome (ARDS). Treatments of post-COVID lung disease are being investigated with anti-fibrotic agents being investigated for the prevention of post-COVID lung fibrosis. The etiology of post-COVID lung disease may be a sequela of prolonged mechanical ventilation, COVID-induced ARDS or direct injury from the virus. Future research is needed to determine the long-term persistence of post-COVID lung disease, its impact on patients and ways to prevent or treat it. |
format | Online Article Text |
id | pubmed-8369881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Radiological Society of North America |
record_format | MEDLINE/PubMed |
spelling | pubmed-83698812021-08-17 CT of Postacute Lung Complications of COVID-19 Solomon, Joshua J. Heyman, Brooke Ko, Jane P. Condos, Rany Lynch, David A. Radiology Review The acute course of coronavirus disease 2019 (COVID-19) is variable and ranges from asymptomatic infection to fulminant respiratory failure. Patients recovering from COVID-19 can have persistent symptoms and computed tomography (CT) abnormalities of variable severity. At 3 months after acute infection, a subset of patients will have CT abnormalities that include ground glass abnormalities (GGO) and subpleural bands with concomitant pulmonary function abnormalities. At 6 months after acute infection, some patients have persistent CT changes to include the resolution of GGOs seen in the early recovery phase and the persistence or development of changes suggestive of fibrosis such as reticulation with or without parenchymal distortion. Predictors of post-COVID lung disease include need for intensive care unit (ICU) admission, mechanical ventilation, higher inflammatory markers, longer hospital stay and a diagnosis of acute respiratory distress syndrome (ARDS). Treatments of post-COVID lung disease are being investigated with anti-fibrotic agents being investigated for the prevention of post-COVID lung fibrosis. The etiology of post-COVID lung disease may be a sequela of prolonged mechanical ventilation, COVID-induced ARDS or direct injury from the virus. Future research is needed to determine the long-term persistence of post-COVID lung disease, its impact on patients and ways to prevent or treat it. Radiological Society of North America 2021-08-10 /pmc/articles/PMC8369881/ /pubmed/34374591 http://dx.doi.org/10.1148/radiol.2021211396 Text en 2021 by the Radiological Society of North America, Inc. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Review Solomon, Joshua J. Heyman, Brooke Ko, Jane P. Condos, Rany Lynch, David A. CT of Postacute Lung Complications of COVID-19 |
title | CT of Postacute Lung Complications of COVID-19 |
title_full | CT of Postacute Lung Complications of COVID-19 |
title_fullStr | CT of Postacute Lung Complications of COVID-19 |
title_full_unstemmed | CT of Postacute Lung Complications of COVID-19 |
title_short | CT of Postacute Lung Complications of COVID-19 |
title_sort | ct of postacute lung complications of covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369881/ https://www.ncbi.nlm.nih.gov/pubmed/34374591 http://dx.doi.org/10.1148/radiol.2021211396 |
work_keys_str_mv | AT solomonjoshuaj ctofpostacutelungcomplicationsofcovid19 AT heymanbrooke ctofpostacutelungcomplicationsofcovid19 AT kojanep ctofpostacutelungcomplicationsofcovid19 AT condosrany ctofpostacutelungcomplicationsofcovid19 AT lynchdavida ctofpostacutelungcomplicationsofcovid19 |